Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Pancreatic Neoplasms 4Sarcoma 2Neoplasm Metastasis 2Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Melanoma 1Glioma 1Glioblastoma 1

Interventions

Doxorubicin 33Ifosfamide 23Gemcitabine 19pazopanib 18Cyclophosphamide 16Radiotherapy 15pembrolizumab 13Filgrastim 12Docetaxel 12Bevacizumab 10Vincristine 9Sirolimus 9Irinotecan 9Etoposide 9olaratumab 7eribulin 7Sorafenib 7Radiation 7temsirolimus 6Temozolomide 6Mesna 6Magnetic Resonance Spectroscopy 6Cisplatin 6tazemetostat 5cixutumumab 5Trabectedin 5Radiosurgery 5Nivolumab 5Ipilimumab 5Granulocyte Colony-Stimulating Factor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Sarcoma × TH 302 × Clear all
NCT00742963 2025-05-13

Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma

ImmunoGenesis

Phase 1/2 Completed
107 enrolled 7 charts
Sarcoma

Sarcoma

NCT02255110 2018-12-14

A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Merck KGaA, Darmstadt, Germany

Phase 2 Terminated
6 enrolled 6 charts
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡